Clinical assessment reports patient-derived organoid testing feasibility in refractory pancreatic ductal adenocarcinoma, suggesting potential functional precision oncology utility.
Patient-derived organoids (PDOs) are promising tumor avatars that could enable ex vivo drug tests to personalize patients' treatments in the frame of functional precision oncology. However, clinical evidence remains scarce. This study aims to evaluate whether PDOs can be implemented in clinical practice to benefit patients with advanced refractory pancreatic ductal adenocarcinoma (PDAC).
No takes yet. Share an insight, caveat, or question.
Boilève et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: